FDA issued a Warning Letter to BioReliance Corporation on 1/5/2009 for a previous inspection.
483 BioReliance Feb 2009

483 BioReliance Feb 2009

Daniel Azar FDA, Ernest Bizjak FDA, Lakisha Williams FDA$119.00 - Available Now

FDA investigators audited the BioReliance - Rockville, MD, United States facility and issued inspectional observations (via FDA 483) on 18 Feb 2009.

Product details

  • Category: Human Drugs / Biologics
  • Inspection end: 18 Feb 2009
  • Location: Rockville, United States
  • FEI: 1122041
Add To Cart